BCAX
Bicara Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.89
−0.78%Nov 2, 2026, 13:30 UTC
Bicara Therapeutics Inc. announced that it will report its third-quarter 2026 financial results and business updates before the market opens on November 9, 2026, and host a conference call at 8:30 a.m. ET that day.
Source:Aug 11, 2026, 15:58 UTC
Bicara Therapeutics initiated the FORTIFI-FLEX trial, a pivotal Phase III study, and outlined an interim analysis timeline for mid-2027.
Source:Aug 11, 2026, 14:06 UTC
Bicara Therapeutics announced leadership changes during its Q2 2026 earnings call.
Jul 28, 2026, 00:00 UTC
Jeremy Bender was appointed as a Class I Director of the Board of Directors and a member of the Audit Committee and Launch Readiness Committee of Bicara Therapeutics Inc., effective July 28, 2026.
Jul 28, 2026, 00:00 UTC
Kiran Mazumdar-Shaw retired from the Board of Directors and the Nominating and Corporate Governance Committee of Bicara Therapeutics Inc., effective July 28, 2026.